|
1
|
Fearon KC, Voss AC and Hustead DS; Cancer
Cachexia Study Group: Definition of cancer cachexia: Effect of
weight loss, reduced food intake, and systemic inflammation on
functional status and prognosis. Am J Clin Nutr. 83:1345–1350.
2006.PubMed/NCBI
|
|
2
|
Tazi E and Errihani H: Treatment of
cachexia in oncology. Indian J Palliat Care. 16:129–137. 2010.
|
|
3
|
Aoyagi T, Terracina KP, Raza A, Matsubara
H and Takabe K: Cancer cachexia, mechanism and treatment. World J
Gastrointest Oncol. 7:17–29. 2015.PubMed/NCBI
|
|
4
|
Ozola Zalite I, Zykus R, Francisco
Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM and Lyadov
V: Influence of cachexia and sarcopenia on survival in pancreatic
ductal adenocarcinoma: A systematic review. Pancreatology.
15:19–24. 2015. View Article : Google Scholar
|
|
5
|
Grabiec K, Burchert M, Milewska M,
Błaszczyk M and Grzelkowska-Kowalczyk K: Systemic and local
mechanisms leading to cachexia in cancer. Postepy hig Med Dosw
(Online). 67:1397–1409. 2013.In Polish. View Article : Google Scholar
|
|
6
|
Onesti JK and Guttridge DC: Inflammation
based regulation of cancer cachexia. BioMed Res Int.
2014:1684072014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tamura S, Ouchi KF, Mori K, Endo M,
Matsumoto T, Eda H, Tanaka Y, Ishitsuka H, Tokita H and Yamaguchi
K: Involvement of human interleukin 6 in experimental cachexia
induced by a human uterine cervical carcinoma xenograft. Clin
Cancer Res. 1:1353–1358. 1995.PubMed/NCBI
|
|
8
|
Enomoto A, Rho MC, Fukami A, hiraku O,
Komiyama K and hayashi M: Suppression of cancer cachexia by
20S,21-epoxy-resi bufogenin-3-acetate-a novel nonpeptide IL-6
receptor antagonist. Biochem Biophys Res Commun. 323:1096–1102.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ando K, Takahashi F, Kato M, Kaneko N, Doi
T, Ohe Y, Koizumi F, Nishio K and Takahashi K: Tocilizumab, a
proposed therapy for the cachexia of Interleukin6-expressing lung
cancer. PLoS One. 9:e1024362014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Madeddu C, Macciò A, Panzone F, Tanca FM
and Mantovani G: Medroxyprogesterone acetate in the management of
cancer cachexia. Expert Opin Pharmacother. 10:1359–1366. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mantovani G, Macciò A, Lai P, Massa E,
Ghiani M and Santona MC: Cytokine involvement in cancer
anorexia/cachexia: Role of megestrol acetate and
medroxyprogesterone acetate on cytokine downregulation and
improvement of clinical symptoms. Crit Rev Oncog. 9:99–106. 1998.
View Article : Google Scholar
|
|
12
|
Inui A: Cancer anorexia-cachexia syndrome:
Current issues in research and management. CA Cancer J Clin.
52:72–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JK, Kim JH and Shin HK: Therapeutic
effects of the oriental herbal medicine Sho-saiko-to on liver
cirrhosis and carcinoma. Hepatol Res. 41:825–837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimizu I: Sho-saiko-to: Japanese herbal
medicine for protection against hepatic fibrosis and carcinoma. J
Gastroenterol Hepatol. 15:D84–D90. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mizushima Y, Kashii T, Tokimitsu Y and
Kobayashi M: Cytotoxic effect of herbal medicine Sho-saiko-to on
human lung-cancer cell-lines in vitro. Oncol Rep. 2:91–94.
1995.PubMed/NCBI
|
|
16
|
Yano H, Mizoguchi A, Fukuda K, Haramaki M,
Ogasawara S, Momosaki S and Kojiro M: The herbal medicine
Sho-saiko-to inhibits proliferation of cancer cell lines by
inducing apoptosis and arrest at the G0/G1 phase. Cancer Res.
54:448–454. 1994.PubMed/NCBI
|
|
17
|
Oh YC, Cho WK, Jeong YH, Im GY, Lee KJ,
Yang HJ and Ma JY: Anti-inflammatory effect of Sosihotang via
inhibition of nuclear factor-κB and mitogen-activated protein
kinases signaling pathways in lipopolysaccharide-stimulated RAW
264.7 macrophage cells. Food Chem Toxicol. 53:343–351. 2013.
View Article : Google Scholar
|
|
18
|
Barton BE: IL-6-like cytokines and cancer
cachexia: Consequences of chronic inflammation. Immunol Res.
23:41–58. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
MacDonald N: Cancer cachexia and targeting
chronic inflammation: A unified approach to cancer treatment and
palliative/supportive care. J Support Oncol. 5:157–162.
2007.PubMed/NCBI
|
|
20
|
Deans C and Wigmore SJ: Systemic
inflammation, cachexia and prognosis in patients with cancer. Curr
Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bonetto A, Aydogdu T, Kunzevitzky N,
Guttridge DC, Khuri S, Koniaris LG and Zimmers TA: STAT3 activation
in skeletal muscle links muscle wasting and the acute phase
response in cancer cachexia. PLoS One. 6:e225382011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lokireddy S, Wijesoma IW, Bonala S, Wei M,
Sze SK, McFarlane C, Kambadur R and Sharma M: Myostatin is a novel
tumoral factor that induces cancer cachexia. Biochem J. 446:23–36.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Costelli P, Muscaritoli M, Bonetto A,
Penna F, Reffo P, Bossola M, Bonelli G, Doglietto GB, Baccino FM
and Rossi Fanelli F: Muscle myostatin signalling is enhanced in
experimental cancer cachexia. Eur J Clin Invest. 38:531–538. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jespersen J, Kjaer M and Schjerling P: The
possible role of myostatin in skeletal muscle atrophy and cachexia.
Scand J Med Sci Sports. 16:74–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Langen RC, Schols AM, Kelders MC, Wouters
EF and Janssen-Heininger YM: Inflammatory cytokines inhibit
myogenic differentiation through activation of nuclear
factor-kappaB. FASEB J. 15:1169–1180. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Donohoe CL, Ryan AM and Reynolds JV:
Cancer cachexia: Mechanisms and clinical implications.
Gastroenterol Res Pract. 2011:6014342011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fujitsuka N, Asakawa A, Amitani H, Hattori
T and Inui A: Efficacy of ghrelin in cancer cachexia: Clinical
trials and a novel treatment by Rikkunshito. Crit Rev Oncog.
17:277–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujitsuka N and Uezono Y: Rikkunshito, a
ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front
Pharmacol. 5:2712014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yae S, Takahashi F, Yae T, Yamaguchi T,
Tsukada R, Koike K, Minakata K, Murakami A, Nurwidya F, Kato M, et
al: Hochuekkito (TJ-41), a kampo formula, ameliorates cachexia
induced by colon 26 adenocarcinoma in mice. Evid Based Complement
Alternat Med. 2012:9769262012. View Article : Google Scholar
|
|
30
|
Choi YK, Jung KY, Woo SM, Yun YJ, Jun CY,
Park JH, Shin YC, Cho SG and Ko SG: Effect of Sipjeondaebo-tang on
cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice.
Mediators Inflamm. 2014:7365632014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iizuka N, Miyamoto K, hazama S, Yoshino S,
Yoshimura K, Okita K, Fukumoto T, Yamamoto S, Tangoku A and Oka M:
Anticachectic effects of Coptidis rhizoma, an anti-inflammatory
herb, on esophageal cancer cells that produce interleukin 6. Cancer
Lett. 158:35–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Camargo CA, da Silva ME, da Silva RA,
Justo GZ, Gomes-Marcondes MC and Aoyama H: Inhibition of tumor
growth by quercetin with increase of survival and prevention of
cachexia in Walker 256 tumor-bearing rats. Biochem Biophys Res
Commun. 406:638–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim HM, Kim YY, Moon HS, Lee EH, Moon SJ
and An NH: Inhibitory effect of anaphylactic reaction of
Sosiho-Tang. Immunopharmacol Immunotoxicol. 20:567–578. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JJ, Kim T, Cho WK and Ma JY:
Antithrombotic and anti-platelet activities of Soshiho-tang
extract. BMC Complement Altern Med. 13:1372013. View Article : Google Scholar
|
|
35
|
Su GY, Yang JY, Wang F, Xiong ZL, Hou Y,
Zhang K, Song C, Ma J, Song SJ, Teng HF, et al: Xiaochaihutang
prevents depressive-like behaviour in rodents by enhancing the
serotonergic system. J Pharm Pharmacol. 66:823–834. 2014.
|
